MOR.F - MorphoSys AG

Frankfurt - Frankfurt Delayed price. Currency in EUR

MorphoSys AG

Semmelweisstrasse 7
Planegg 82152
Germany
49 89 89927 0
http://www.morphosys.com

SectorHealthcare
IndustryBiotechnology
Full-time employees426

Key executives

NameTitlePayExercisedYear born
Dr. Jean-Paul KressCEO & Management Board Member1.57MN/A1965
Mr. Jens H. HolsteinCFO & Member of the Management Board1.43MN/A1964
Dr. Malte PetersChief Devel. Officer & Member of the Management Board1.37MN/A1962
Mr. Klaus De WallHead of Accounting & TaxN/AN/AN/A
Ms. Lara Smith WeberHead of Controlling, Corp. Fin. & Corp. Devel.N/AN/AN/A
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma. Its product pipeline includes MOR208, an antibody for the treatment of haematological cancers; MOR202, an antibody for the treatment of multiple myeloma and other cancers, as well as other autoimmune diseases; MOR106, an antibody for rheumatoid arthritis; and MOR107, a lanthipeptide for oncology diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize MOR202 in China, Taiwan, Hong Kong, and Macao; a strategic alliance with the LEO Pharma A/S to develop peptide-derived therapeutics for unmet medical needs; and a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys' investigational compound tafasitamab (MOR208). The company was founded in 1992 and is headquartered in Planegg, Germany.

Corporate governance

MorphoSys AG’s ISS governance QualityScore as of 3 December 2019 is 1. The pillar scores are Audit: 1; Board: 1; Shareholder rights: 1; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.
By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more